Press release
Fragile X Syndrome Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene
The Key Fragile X Syndrome Companies in the market incude - Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Craig Erickson, Nova Mentis Life Science, and others.DelveInsight's "Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Fragile X Syndrome, historical and forecasted epidemiology as well as the Fragile X Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Fragile X Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fragile X Syndrome Market Forecast [https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Fragile X Syndrome Market Report:
*
The Fragile X Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
DelveInsight's epidemiology model estimates that the total diagnosed prevalent cases of FXS in the 7MM were around 122,000 in 2023. This figure is expected to grow during the forecast period (2024-2034) due to heightened awareness, improved screening, and advancements in genetic testing.
*
In 2023, the US had the highest number of diagnosed prevalent cases of FXS, totaling around 71,000 cases, whereas Spain reported the lowest, with nearly 5,900 cases.
*
In 2023, among the EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of FXS, with about 9,700 cases, followed by France with around 7,900 cases and the UK with nearly 7,800 cases.
*
In 2023, around 42,000 males and 29,000 females in the US were diagnosed with FXS, indicating a greater prevalence in males than in females.
*
In Japan, in 2023, there were about 5,700 cases in the 0-11 age group, 2,300 cases in the 12-17 age group, and 5,000 cases among individuals over 18, reflecting differences in prevalence across age groups.
*
Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Craig Erickson, Nova Mentis Life Science, and others
*
Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), Gaboxadol, ZYN002, Psilocybin, and others
*
The Fragile X Syndrome epidemiology based on gender analyzed that males are affected more as compared to females, in the case of Fragile X Syndrome (FXS)
*
The Fragile X Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fragile X Syndrome pipeline products will significantly revolutionize the Fragile X Syndrome market dynamics.
Fragile X Syndrome Overview
Fragile X Syndrome is a genetic condition characterized by intellectual disability, behavioral and learning challenges, and various physical features. It is caused by a mutation in the FMR1 gene located on the X chromosome. This mutation leads to a reduction or absence of the FMR1 protein, which is essential for normal brain development. Fragile X Syndrome is the most common inherited cause of intellectual disability, affecting males more severely than females.
Get a Free sample for the Fragile X Syndrome Market Report:
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market [https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Fragile X Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Fragile X Syndrome Epidemiology Segmentation:
The Fragile X Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Fragile X Syndrome
*
Prevalent Cases of Fragile X Syndrome by severity
*
Gender-specific Prevalence of Fragile X Syndrome
*
Diagnosed Cases of Episodic and Chronic Fragile X Syndrome
Download the report to understand which factors are driving Fragile X Syndrome epidemiology trends @ Fragile X Syndrome Epidemiology Forecast [https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Fragile X Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fragile X Syndrome market or expected to get launched during the study period. The analysis covers Fragile X Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Fragile X Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Fragile X Syndrome Therapies and Key Companies
*
Zygel: Zynerba Pharmaceuticals
*
Acamprosate: Confluence Pharmaceuticals
*
BPN14770: Tetra Therapeutics
*
Trofinetide: Neuren Pharmaceuticals
*
Sulindac (HLX-0201): Healx
*
Gaboxadol: Craig Erickson
*
ZYN002: Zynerba Pharmaceuticals
*
Psilocybin: Nova Mentis Life Science
Discover more about therapies set to grab major Fragile X Syndrome market share @ Fragile X Syndrome Treatment Market [https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Fragile X Syndrome Market Strengths
*
Growing Research and development are increasing the demand for FXS treatment.
*
Advances in DNA technology, including CRISPRCas9, have been used to correct the expanded CGG repeat in induced pluripotent stem cells. Eventually, it might be possible to add these corrected stem cells into the central nervous systems of those with FXS
Fragile X Syndrome Market Opportunities
*
The rise in the prevalence of FXS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable.
*
Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive FXS market.
Scope of the Fragile X Syndrome Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Craig Erickson, Nova Mentis Life Science, and others
*
Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), Gaboxadol, ZYN002, Psilocybin, and others
*
Fragile X Syndrome Therapeutic Assessment: Fragile X Syndrome current marketed and Fragile X Syndrome emerging therapies
*
Fragile X Syndrome Market Dynamics: Fragile X Syndrome market drivers and Fragile X Syndrome market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Fragile X Syndrome Unmet Needs, KOL's views, Analyst's views, Fragile X Syndrome Market Access and Reimbursement
To know more about Fragile X Syndrome companies working in the treatment market, visit @ Fragile X Syndrome Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Fragile X Syndrome Market Report Introduction
2. Executive Summary for Fragile X Syndrome
3. SWOT analysis of Fragile X Syndrome
4. Fragile X Syndrome Patient Share (%) Overview at a Glance
5. Fragile X Syndrome Market Overview at a Glance
6. Fragile X Syndrome Disease Background and Overview
7. Fragile X Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Fragile X Syndrome
9. Fragile X Syndrome Current Treatment and Medical Practices
10. Fragile X Syndrome Unmet Needs
11. Fragile X Syndrome Emerging Therapies
12. Fragile X Syndrome Market Outlook
13. Country-Wise Fragile X Syndrome Market Analysis (2020-2034)
14. Fragile X Syndrome Market Access and Reimbursement of Therapies
15. Fragile X Syndrome Market Drivers
16. Fragile X Syndrome Market Barriers
17. Fragile X Syndrome Appendix
18. Fragile X Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fragile-x-syndrome-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-novartis-neuren-pharma-roche-seaside-therapeutics-inc-marinus-pharma-lysogene]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fragile X Syndrome Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene here
News-ID: 3680663 • Views: …
More Releases from ABNewswire

Best Employer of Record (EOR) Services for 2025: Remofirst, Oyster HR, and Deel …
EORService.nl announces its 2025 ranking of top Employer of Record providers, highlighting Remofirst, Oyster HR, and Deel as global leaders.
AMERSFOORT, Netherlands - Sep 1, 2025 - EORService.nl has announced its 2025 list of the Best Employer of Record (EOR) Services, helping companies expand into new markets quickly and compliantly. The report highlights three providers leading the industry this year: Remofirst [https://eorservice.nl/go/remofirst/], Oyster HR, and Deel.
An Employer of Record (EOR) is…

Fish Delish Canada Launches, Bringing a New Era of Premium Smoked Salmon to Cana …
Fish Delish Canada has officially launched, introducing Canadians to a new era of premium, small-batch smoked salmon. Based in Caledon, Ontario, the licensed, kosher-certified producer offers handcrafted cold-smoked lox, innovative gravlax, candied steelhead, and Canada's first kosher salmon jerky. With a sashimi-like texture, clean buttery taste, and nationwide shipping, Fish Delish is redefining what smoked salmon can be. Now available for nationwide delivery at smokedsalmoncanada.com
Caledon, Ontario - A new Canadian…

Rajeshwari Dental Clinic Emerges as a Comprehensive Dental Hub in Vasai
By presenting extraordinary teeth whitening in Vasai, specific root canal treatment in Vasai, and toddler-friendly, high-quality kids dentistry in Vasai, Rajeshwari Dental Clinic has redefined excellence in dental care. Recognised as a top-tier dental hospital in Vasai, it remains the primary choice for those looking for an honest dentist across a broad spectrum of dental needs.
In a place witnessing increasing demand for holistic oral healthcare, Rajeshwari Dental Clinic has set…

Dermavision - The Skin Clinic in Delhi taps on new advancements in non-invasive …
Revered as the best skin clinic in Delhi for its highly advanced science-backed skin and hair treatment services, Dermavision - The Skin Clinic plans to harness the power of new advancements and technologies in non-invasive hair loss treatment to prevent hair loss and stimulate hair growth.
Dermavision - The Skin Clinic, a specialized science-backed dermatology clinic in the capital, in line with its new approach to hair loss treatment in Delhi…
More Releases for Fragile
Fragile X Syndrome Fxs Treatment Market Size, Share & Trends [2035]
The Fragile X Syndrome Market Is Set To Grow At An Estimated CAGR Of 8.4% From 2025 To 2034, Rising From $1.2 Billion In 2024 To $2.6 Billion By 2034.
On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Fragile X Syndrome Fxs Treatment market goods. The market study excludes key regions that are…
Fragile X-Syndrome Therapeutics Market: Treatment Strategies and Emerging Therap …
The Summary of the Fragile X-Syndrome Market Report
The MMR offers a concise depiction of the "Fragile X-Syndrome Market" industry, delivering an in-depth analysis of the Fragile X-Syndrome market. It emphasizes standard subjects while tailoring data to suit specific requirements. This overview serves as a comprehensive guide for investors seeking insights into the current landscape of the Fragile X-Syndrome industry.
Fragile X-Syndrome Market Expansion
Fragile X-Syndrome Market size is expected to grow at…
Sparkling Wine market status most fragile speculative growth trends
A new statistical surveying study titled Sparkling Wine Market investigates a few critical features identified with Sparkling Wine Market covering industry condition, division examination, and focused scene. Down to earth ideas of the market are referenced in a straightforward and unassuming way in this report. A far-reaching and exhaustive essential investigation report features various actualities, for example, improvement factors, business upgrade systems, measurable development, monetary benefit or misfortune to support…
IT Education and Training MARKET STATUS – MOST FRAGILE & SPECULATIVE GROWTH TR …
” The newly added research report illustrating details on global IT Education and Training market delivers key insights on specific market elements such as competition intensity, regional growth opportunities, vendor profiles and requisite understanding of most potential growth triggers and vendor activities that harbinger growth in global IT Education and Training market. Crucial details on SWOT analysis, PESTEL analysis and Porter’s Five Forces analytical reviews have been professed with great…
Life Sciences Software market status most fragile speculative growth trends
Detailed research added by Ample Market Research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Life Sciences Software market in the latest research report. The research study concisely dissects the Life Sciences Software and unearths valuable estimations pertaining to the profit projections, market size, sales capacity, and numerous other crucial parameters. Also, the Life Sciences Software Market report appraises the industry fragments…
Fragile X Syndrome-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome-Pipeline Review, H2 2018, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.
Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay…